Influence of genetic polymorphism of CYP2C19 on pharmacokinetics and pharmacodynamics of clopidogrel therapy in Indian population

Trial Profile

Influence of genetic polymorphism of CYP2C19 on pharmacokinetics and pharmacodynamics of clopidogrel therapy in Indian population

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 31 Aug 2016

At a glance

  • Drugs Clopidogrel (Primary)
  • Indications Cardiovascular disorders; Thrombosis; Venous thromboembolism
  • Focus Pharmacodynamics; Pharmacogenomic
  • Most Recent Events

    • 01 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top